Publications by authors named "Greg Wiseman"

Claim this Profile
F
Fibrinogen Early In Severe paediatric Trauma studY (FEISTY junior): protocol for a randomised controlled trial.
Shane George, Elizabeth Wake, Melanie Jansen, John Roy, Sharon Maconachie, Greg Wiseman

BMJ Open· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Case Report: Fatal Pediatric Melioidosis Despite Optimal Intensive Care.
Alice Young, Catherine Tacon, Simon Smith, Ben Reeves, Greg Wiseman

Am J Trop Med Hyg· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Primary amoebic meningoencephalitis in North Queensland: the paediatric experience.
Claire L Nicholls, Fiona Parsonson, Lawrence Ek Gray, Adele Heyer, Steven Donohue, Greg Wiseman

Med J Aust· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioembolisation for liver metastases: results from a prospective 151 patient multi-institutional phase II study.
Al B Benson, Jean-Francois Geschwind, Mary F Mulcahy, William Rilling, Gary Siskin, Greg Wiseman

Eur J Cancer· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.
Leo I Gordon, Thomas Witzig, Arturo Molina, Myron Czuczman, Christos Emmanouilides, Greg Wiseman

Clin Lymphoma· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.
Leo I Gordon, Arturo Molina, Thomas Witzig, Christos Emmanouilides, Andrew Raubtischek, Greg Wiseman

Blood· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.
Andrew M Scott, Greg Wiseman, Sydney Welt, Alex Adjei, Fook-Thean Lee

Clin Cancer Res· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Leo I Gordon, Thomas E Witzig, Greg A Wiseman, Ian W Flinn, Stewart S Spies

Semin Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Y
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.
Leo I Gordon, Thomas E Witzig, Greg A Wiseman, Ian W Flinn, Stewart S Spies

Semin Oncol· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis